FS.12: Featured Science Potpourri (AHA 2026) - Oct 8, 2026 - Pres time: Nov 9, 2026; 01:30 PM - 02:45 PM; Location: Heart Theater 2‚ Science and Technology Hall‚ South Hall‚ Heart Hub; In-Person; "VESALIUS-CV – Health Economic Outcomes in the Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke Randomized Trial Lp(a)FRONTIERS EXPANSION – Efficacy and Safety of Pelacarsen in Black/African American and Hispanic Participants With Elevated Lipoprotein(a) and Established Atherosclerotic Cardiovascular Disease T2T – Test 2 Treat: A Hybrid Effectiveness-Implementation Trial to Improve LDL-C Testing and Management After Hospitalization for Atherosclerotic Cardiovascular Disease TIME-SGLT2 TrialTreating the Metabolic Syndrome With a Sodium-Glucose Cotransporter-2 Inhibitor: A Randomised Controlled Trial ECG-AI-First Sequential Screening With NT-proBNP for Heart Failure Risk: The HeartShare/AMP-HF Pooled Cohort Study Recover-Autonomic - Results From Primary Analysis of the Coordinated versus Usual Nonpharmacologic Care for Postural Orthostatic Tachycardia Syndrome in Long COVID: A Pooled Analysis From the..."
Late-breaking abstract • Atherosclerosis • Cardiovascular • Heart Failure • Metabolic Disorders • Myocardial Infarction • Novel Coronavirus Disease
|
|
Melvin Echols; Dorairaj Prabhakaran
|